Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Current Liabilities (2018 - 2025)

Bicycle Therapeutics' Total Current Liabilities history spans 8 years, with the latest figure at $57.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 15.24% year-over-year to $57.0 million; the TTM value through Dec 2025 reached $57.0 million, down 15.24%, while the annual FY2025 figure was $57.0 million, 15.24% down from the prior year.
  • Total Current Liabilities reached $57.0 million in Q4 2025 per BCYC's latest filing, down from $69.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $77.4 million in Q2 2025 to a low of $20.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $52.5 million, with a median of $54.9 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: soared 77.64% in 2022, then fell 19.12% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $36.2 million in 2021, then surged by 47.2% to $53.3 million in 2022, then skyrocketed by 30.36% to $69.5 million in 2023, then fell by 3.32% to $67.2 million in 2024, then decreased by 15.24% to $57.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Total Current Liabilities are $57.0 million (Q4 2025), $69.3 million (Q3 2025), and $77.4 million (Q2 2025).